At the 2023 ASCO Annual Meeting, Wayshine Biopharm presented the preliminary results from the dose-escalation phase of the first-in-human Phase I clinical trial for its self-developed fourth-generation EGFR inhibitor, WSD0922-FU. The presentation disclosed the drug's safety profile and preliminary efficacy in patients with osimertinib-resistant NSCLC, established the maximum tolerated dose (MTD), and highlighted its potential to overcome resistance mutations, garnering widespread attention in the industry.